A Phase 3, randomized, double-blind study comparing Upadacitinib (ABT-494) to placebo and to Adalimumab in subjects with active Psoriatic Arthritis who have a history of Inadequate Response to atleast one Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)